The neurologic manifestations of the acute porphyrias

Journal of Clinical Neuroscience

Volumn 18, Issue 9, 2011, Pages 1147-1153

  Simon, Neil G ^a   Herkes, Geoffrey K ^a  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Haem; Neuropathy; Porphyria

Indexed keywords

AMINOLEVULINIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; COPROPORPHYRIN; ETIRACETAM; GABAPENTIN; GONADORELIN DERIVATIVE; HEMATIN; HEME; HEME ARGINATE; NARCOTIC ANALGESIC AGENT; PARACETAMOL; PORPHOBILINOGEN; PORPHYRIN; PROPOFOL; PROTOPORPHYRIN; UROPORPHYRIN;

ACUTE INTERMITTENT PORPHYRIA; AUTONOMIC NEUROPATHY; BIOCHEMISTRY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; DISEASE CLASSIFICATION; EPILEPTIC STATE; FECES ANALYSIS; FOCAL EPILEPSY; HEME SYNTHESIS; HEREDITY; HUMAN; HYPERTENSION; NEUROLOGIC DISEASE; NEUROPATHOLOGY; PAIN; PERIPHERAL NEUROPATHY; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; REVIEW; SEIZURE; TACHYCARDIA; URINALYSIS;

ADULT; FEMALE; HEME; HUMANS; NERVOUS SYSTEM DISEASES; PERIPHERAL NERVES; PORPHYRIAS; PORPHYRINS;

EID: 79960993616     PISSN: 09675868     EISSN: 15322653     Source Type: Journal    
DOI: 10.1016/j.jocn.2011.01.003     Document Type: Review

References (84)

1. Sassa S. Modern diagnosis and management of the porphyrias. Br J Haematol 2006;135:281-92. (Pubitemid 44484835)
2. Bishop DF, Henderson AS, Astrin KH. Human delta-aminolevulinate synthase: assignment of the housekeeping gene to 3p21 and the erythroid-specific gene to the X chromosome. Genomics 1990;7:207-14. (Pubitemid 20235576)
3. Thadani H, Deacon A, Peters T. Diagnosis and management of porphyria. BMJ 2000;320:1647-51. (Pubitemid 30364637)
4. Herrick AL, McColl KE. Acute intermittent porphyria. Best Pract Res Clin Anaesthesiol 2005;19:235-49.
5. Oritz de Montellano PR, Correia MA. Suicidal destruction of cytochrome P-450 during oxidative drug metabolism. Annu Rev Pharmacol Toxicol 1983;23:481-503. (Pubitemid 13079386)
6. Abel G, Palmer-Toy D. Heme synthesis and catabolism. In: McClatchkey KD, editor. Clinical laboratory medicine. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2002. p. 407-17.
7. Doss M, Sixel-Dietrich F, Verspohl F. "Glucose effect" and rate limiting function of uroporphyrinogen synthase on porphyrin metabolism in hepatocyte culture: relationship with human acute hepatic porphyrias. J Clin Chem Clin Biochem 1985;23:505-13. (Pubitemid 16255800)
8. Foran SE, Abel G. Guide to porphyrias. A historical and clinical perspective. Am J Clin Pathol 2003;119(Suppl.):S86-93.
9. Hengstman GJ, de Laat KF, Jacobs B, et al. Sensorimotor axonal polyneuropathy without hepatic failure in erythropoietic protoporphyria. J Clin Neuromuscul Dis 2009;11:72-6.
10. Kauppinen R. Porphyrias. Lancet 2005;365:241-52.
11. Murphy GM. The cutaneous porphyrias: a review. Br J Dermatol 1999;140:573-81. (Pubitemid 29191373)
12. Meissner P, Adams P, Kirsch R. Allosteric inhibition of human lymphoblast and purified porphobilinogen deaminase by protoporphyrinogen and coproporphyrinogen. A possible mechanism for the acute attack of variegate porphyria. J Clin Invest 1993;91:1436-44. (Pubitemid 23127344)
13. Maruno M, Furuyama K, Akagi R, et al. Highly heterogeneous nature of delta-aminolevulinate dehydratase (ALAD) deficiencies in ALAD porphyria. Blood 2001;97:2972-8.
14. Badminton MN, Elder GH. Molecular mechanisms of dominant expression in porphyria. J Inherit Metab Dis 2005;28:277-86. (Pubitemid 40723864)
15. Nordmann Y, Puy H, Da Silva V, et al. Acute intermittent porphyria: prevalence of mutations in the porphobilinogen deaminase gene in blood donors in France. J Intern Med 1997;242:213-7. (Pubitemid 27400433)
16. Eales L, Dowdle EB, Sweeney GD. The acute porphyric attack. I. The electrolyte disorder of the acute porphyric attack and the possible role of delta-aminolaevulic acid. S Afr Med J 1971;25:89-97.
17. Andersson C, Nilsson A, Backstrom T. Atypical attack of acute intermittent porphyria-paresis but no abdominal pain. J Intern Med 2002;252:265-70.
18. Gonzalez-Arriaza HL, Bostwick JM. Acute porphyrias: a case report. Am J Psychiatry 2003;160:450-8.
19. Ellencweig N, Schoenfeld N, Zemishlany Z. Acute intermittent porphyria: psychosis as the only clinical manifestation. Isr J Psychiatry Relat Sci 2006;43:52-6. (Pubitemid 44090666)
20. Pischik E, Bulyanitsa A, Kazakov V, et al. Clinical features predictive of a poor prognosis in acute porphyria. J Neurol 2004;251:1538-41. (Pubitemid 40169486)
21. Goldberg A. Acute intermittent porphyria: a study of 50 cases. Q J Med 1959;28:183-209.
22. Berlin L, Cotton R. Gastro-intestinal manifestations of porphyria. Am J Dig Dis 1950;17:110-4.
23. Ridley A, Hierons R, Cavanagh JB. Tachycardia and the neuropathy of porphyria. Lancet 1968;2:708-10.
24. Scott L, Bean DW. Psychiatric manifestations of porphyria. S D J Med 1987;40:5-8.
25. Goren MB, Chen C. Acute intermittent porphyria with atypical neuropathy. South Med J 1991;84:668-9.
26. Laiwah AC, Macphee GJ, Boyle P, et al. Autonomic neuropathy in acute intermittent porphyria. J Neurol Neurosurg Psychiatry 1985;48:1025-30. (Pubitemid 16235988)
27. Suarez JI, Cohen ML, Larkin J, et al. Acute intermittent porphyria: clinicopathologic correlation. Report of a case and review of the literature. Neurology 1997;48:1678-83.
28. Albers JW, Robertson Jr WC, Daube JR. Electrodiagnostic findings in acute porphyric neuropathy. Muscle Nerve 1978;1:292-6. (Pubitemid 9023927)
29. Sorensen AW, With TK. Persistent pareses after porphyric attacks. S Afr Med J 1971;25:101-3.
30. Ridley A. The neuropathy of acute intermittent porphyria. Q J Med 1969;38:307-33.
31. Albers JW, Fink JK. Porphyric neuropathy. Muscle Nerve 2004;30:410-22. (Pubitemid 39288143)
32. Vucic S, Kiernan MC, Cornblath DR. Guillain-Barré syndrome: an update. J Clin Neurosci 2009;16:733-41.
33. Kuitwaard K, Bos-Eyssen ME, Blomkwist-Markens PH, et al. Recurrences, vaccinations and long-term symptoms in GBS and CIDP. J Peripher Nerv Syst 2009;14:310-5.
34. Leger JM, Salachas F. Diagnosis of motor neuropathy. Eur J Neurol 2001;8:201-8. (Pubitemid 32476616)
35. Baker EL, Landrigan PJ, Barbour AG, et al. Occupational lead poisoning in the United States: clinical and biochemical findings related to blood lead levels. Br J Ind Med 1979;36:314-22.
36. Dowdle EB, Wilson E, Burger P. Symptomatic porphyria I - the effects of lead on the synthesis of porphyrin and haem. S Afr Med J 1971;25:38-45.
37. Flugel KA, Druschky KF. Electromyogram and nerve conduction in patients with acute intermittent porphyria. J Neurol 1977;214:267-79. (Pubitemid 8063596)
38. Hierons R. Changes in the nervous system in acute porphyria. Brain 1957;80:176-92.
39. Cavanagh JB, Mellick RS. On the nature of the peripheral nerve lesions associated with acute intermittent porphyria. J Neurol Neurosurg Psychiatry 1965;28:320-7.
40. Yamada M, Kondo M, Tanaka M, et al. An autopsy case of acute porphyria with a decrease of both uroporphyrinogen I synthetase and ferrochelatase activities. Acta Neuropathol 1984;64:6-11. (Pubitemid 14095882)
41. Anzil AP, Dozic S. Peripheral nerve changes in porphyric neuropathy: findings in a sural nerve biopsy. Acta Neuropathol 1978;42:121-6. (Pubitemid 9012404)
42. Hsieh CH, Tsai HH, Lu TH, et al. Acute intermittent porphyria with peripheral neuropathy complicated by small-fiber neuropathy. Neuropathology 2007;27:133-8.
43. Santosh PJ, Malhotra S. Varied psychiatric manifestations of acute intermittent porphyria. Biol Psychiatry 1994;36:744-7. (Pubitemid 24365881)
44. Tishler PV, Woodward B, O'Connor J, et al. High prevalence of intermittent acute porphyria in a psychiatric patient population. Am J Psychiatry 1985;142:1430-6. (Pubitemid 16169877)
45. Eales L. The acute porphyria attack. 3. Acute porphyria: the precipitating and aggravating factors. S Afr Med J 1971;25:120-5.
46. Solinas C, Vajda FJ. Epilepsy and porphyria: new perspectives. J Clin Neurosci 2004;11:356-61. (Pubitemid 38578383)
47. Celik M, Forta H, Dalkilic T, et al. MRI reveals reversible lesions resembling posterior reversible encephalopathy in porphyria. Neuroradiology 2002;44:839-41. (Pubitemid 36067877)
48. Utz N, Kinkel B, Hedde JP, et al. MR imaging of acute intermittent porphyria mimicking reversible posterior leukoencephalopathy syndrome. Neuroradiology 2001;43:1059-62. (Pubitemid 33133644)
49. Black KS, Mirsky P, Kalina P, et al. Angiographic demonstration of reversible cerebral vasospasm in porphyric encephalopathy. AJNR Am J Neuroradiol 1995;16:1650-2.
50. Bartynski WS. Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features. AJNR 2008;29:1036-42. (Pubitemid 351954863)
51. Bartynski WS. Posterior reversible encephalopathy syndrome, part 2: controversies surrounding pathophysiology of vasogenic oedema. AJNR 2008;29:1043-9. (Pubitemid 351954864)
52. Kupferschmidt H, Bont A, Schnorf H, et al. Transient cortical blindness and bioccipital brain lesions in two patients with acute intermittent porphyria. Ann Intern Med 1995;123:598-600.
53. White KA, Marletta MA. Nitric oxide synthase is a cytochrome P-450 type hemoprotein. Biochemistry 1992;31:6627-31.
54. McGillion FB, Thompson GG, Goldberg A. Tissue uptake of o-aminolaevulinic acid. Biochem Pharmacol 1975;24:99-301.
55. Monteiro HP, Abdalla DS, Augusto O, et al. Free radical generation during delta-aminolevulinic acid autoxidation: induction by hemoglobin and connections with porphyrinpathies. Arch Biochem Biophys 1989;271:206-16. (Pubitemid 19119832)
56. Oteiza PI, Bechara EJ. 5-Aminolevulinic acid induces lipid peroxidation in cardiolipin-rich liposomes. Arch Biochem Biophys 1993;305:282-7. (Pubitemid 23282909)
57. Hermes-Lima M, Castilho RF, Valle VG, et al. Calcium-dependent mitochondrial oxidative damage promoted by 5-aminolevulinic acid. Biochim Biophys Acta 1992;1180:201-6.
58. Hermes-Lima M, Valle VG, Vercesi AE, et al. Damage to rat liver mitochondria promoted by delta-aminolevulinic acid-generated reactive oxygen species: connections with acute intermittent porphyria and lead-poisoning. Biochim Biophys Acta 1991;1056:57-63.
59. Biempica L, Kosower N, Ma MH, et al. Hepatic porphyrias. Cytochemical and ultrastructural studies of liver in acute intermittent porphyria and porphyria cutanea tarda. Arch Pathol 1974;98:336-43.
60. Smith KJ, Kapoor R, Felts PA. Demyelination: the role of reactive oxygen and nitrogen species. Brain Pathol 1999;9:69-92. (Pubitemid 29056521)
61. Felitsyn N, McLeod C, Shroads AL, et al. The heme precursor delta-aminolevulinate blocks peripheral myelin formation. J Neurochem 2008;106:2068-79.
62. Demasi M, Penatti CA, DeLucia R, et al. The prooxidant effect of 5-aminolevulinic acid in the brain tissue of rats: implications in neuropsychiatric manifestations in porphyrias. Free Radic Biol Med 1996;20:291-9. (Pubitemid 26077851)
63. Kramer S, Viljoen D, Becker D, et al. A possible explanation for the neurological disturbances in the porphyrias. S Afr Med J 1971;25:103-7.
64. Percy VA, Shanley BC. Studies on haem biosynthesis in rat brain. J Neurochem 1979;33:1267-74. (Pubitemid 10133872)
65. Kaji R. Physiology of conduction block in multifocal motor neuropathy and other demyelinating neuropathies. Muscle Nerve 2003;27:285-96. (Pubitemid 36255388)
66. Lin CS, Krishnan AV, Lee MJ, et al. Nerve function and dysfunction in acute intermittent porphyria. Brain 2008;131:2510-9.
67. Horn S, Quasthoff S, Grafe P, et al. Abnormal axonal inward rectification in diabetic neuropathy. Muscle Nerve 1996;19:1268-75. (Pubitemid 26313823)
68. Moore MR, Disler PB. Biochemical diagnosis of the porphyrias. Clin Dermatol 1985;3:24-40.
69. Moore MR, McColl KE. Therapy of the acute porphyrias. Clin Biochem 1989;22:181-8. (Pubitemid 19162802)
70. The American Porphyria Foundation. Drug safety in acute porphyria. 2009; Available from: 〈http://www.porphyriafoundation.com/testing-and-treatment/ drug-safety-in-acute-porphyria/〉.
71. Anderson KE, Spitz IM, Sassa S, et al. Prevention of cyclical attacks of acute intermittent porphyria with a long-acting agonist of luteinizing hormone-releasing hormone. N Engl J Med 1984;311:643-5. (Pubitemid 14027329)
72. Herrick AL, McColl KE, Wallace AM, et al. LHRH analogue treatment for the prevention of premenstrual attacks of acute porphyria. Q J Med 1990;75:355-63. (Pubitemid 20160079)
73. Bonkovsky HL, Barnard GF. The porphyrias. Curr Treat Options Gastroenterol 2000;3:487-500.
74. Tatum WOT, Zachariah SB. Gabapentin treatment of seizures in acute intermittent porphyria. Neurology 1995;45:1216-7.
75. Zaatreh MM. Levetiracetam in porphyric status epilepticus: a case report. Clin Neuropharmacol 2005;28:243-4. (Pubitemid 41579624)
76. Paul F, Meencke HJ. Levetiracetam in focal epilepsy and hepatic porphyria: a case report. Epilepsia 2004;45:559-60. (Pubitemid 38581570)
77. Bhatia R, Vibha D, Srivastava MVP, et al. Use of propofol anesthesia and adjunctive treatment with levetirecetam and gabapentin in managing status epilepticus in a patient of acute intermittent porphyria. Epilepsia 2008;49:934-6. (Pubitemid 351652434)
78. Anderson KE, Bloomer JR, Bonkovsky HL, et al. Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Int Med 2005;142:439-50. (Pubitemid 40365431)
79. Laiwah AC, McColl KE. Management of attacks of acute porphyria. Drugs 1987;34:604-16. (Pubitemid 17147676)
80. Mustajoki P, Nordmann Y. Early administration of heme arginate for acute porphyric attacks. Arch Intern Med 1993;153:2004-8. (Pubitemid 23263562)
81. McColl KEL, Herrick AL, Brodie MJ, et al. Effect of haem arginate therapy on urinary delta- aminolaevulinic acid (ALA) excretion, leucocyte ALA synthase activity and hepatic mono-oxygenase activity in acute porphyria. Proceedings of the International Meeting on Porphyrins and Porphyrias; 1987, 7-10 October; Rome.
82. Mustajoki P, Tenhunen R, Tokola O, et al. Haem arginate in the treatment of acute hepatic porphyrias. Br Med J (Clin Res Ed) 1986;293:538-9. (Pubitemid 16051197)
83. Seth AK, Badminton MN, Mirza D, et al. Liver transplantation for porphyria: who, when and how? Liver Transpl 2005;13:1219-27.
84. Johansson A, Nowak G, Moller C, et al. Non-viral delivery of the porphobilinogen deaminase cDNA into a mouse model of acute intermittent porphyria. Mol Genet Metab 2004;82:20-6. (Pubitemid 38521124)